Entity

Time filter

Source Type

Waltham, MA, United States

Seyfried T.N.,Boston College | Marsh J.,Boston College | Marsh J.,Yeshiva University | Shelton L.M.,Boston College | And 4 more authors.
Epilepsy Research | Year: 2012

Malignant brain cancer persists as a major disease of morbidity and mortality. The failure to recognize brain cancer as a disease of energy metabolism has contributed in large part to the failure in management. As long as brain tumor cells have access to glucose and glutamine, the disease will progress. The current standard of care provides brain tumors with access to glucose and glutamine. The high fat low carbohydrate ketogenic diet (KD) will target glucose availability and possibly that of glutamine when administered in carefully restricted amounts to reduce total caloric intake and circulating levels of glucose. The restricted KD (RKD) targets major signaling pathways associated with glucose and glutamine metabolism including the IGF-1/PI3K/Akt/Hif pathway. The RKD is anti-angiogenic, anti-invasive, anti-inflammatory, and pro-apoptotic when evaluated in mice with malignant brain cancer. The therapeutic efficacy of the restricted KD can be enhanced when combined with drugs that also target glucose and glutamine. Therapeutic efficacy of the RKD was also seen against malignant gliomas in human case reports. Hence, the RKD can be an effective non-toxic therapeutic option to the current standard of care for inhibiting the growth and invasive properties of malignant brain cancer. © 2011 Elsevier B.V. Source


Seyfried T.N.,Boston College | Shelton L.M.,Minerva Biotechnologies | Huysentruyt L.C.,University of California at San Francisco
Neuromethods | Year: 2013

Information is presented on the new VM-M3 mouse model for glioblastoma multiforme (GBM). The VM-M3 tumor arose in the brain of inbred VM strain, which is known to have a high incidence of spontaneous brain tumors. The failure to develop effective treatments for GBM has been due in part to the failure of animal models to manifest the key invasive properties of the disease. Scherer originally described the properties of malignant brain tumors in terms of their invasive behavior independent of cell classification. These properties are referred to as Secondary Structures and involve growth and invasion along blood vessels, through ventricles, white matter tracts, through the corpus callosum and across pial membranes. While extracranial metastasis is not often reported, numerous reports show that GBM can be highly metastatic if the cells gain access to extracranial sites. The VM-M3 GBM model is unique in displaying the Secondary Structures of Scherer and showing systemic metastasis when grown outside the CNS. The VM-M3 cells express the luciferase gene and can be used to assess quantitatively distal CNS invasion. Evidence is presented showing the calorie restriction reduces VM-M3 CNS invasion. The VM-M3 model will be useful for evaluating new therapies for GBM. © 2013 Springer Science+Business Media New York. Source


Minerva Biotechnologies | Entity website

Investor Contact: Ron Axelrod Office: 781-487-0200 X109 Cell: 617-785-9491 Email: raxelrod@minervabio.com Minerva Biotechnologies Corp ...


Minerva Biotechnologies | Entity website

Download a credit application to be approved for invoicing

Discover hidden collaborations